In the BioHarmony Drug Report Database

"Preview" Icon

Polatuzumab vedotin-piiq

Polivy (polatuzumab vedotin) is an antibody pharmaceutical. Polatuzumab vedotin was first approved as Polivy on 2019-06-10. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat b-cell lymphoma. The pharmaceutical is active against B-cell antigen receptor complex-associated protein beta chain.

 

Trade Name

 

Polivy
 

Common Name

 

polatuzumab vedotin
 

ChEMBL ID

 

CHEMBL3301582
 

Indication

 

b-cell lymphoma, large b-cell lymphoma diffuse
 

Drug Class

 

Synthetic analogs of the dolastatin series; monoclonal antibodies: humanized, tumors as target

Image (chem structure or protein)

Polatuzumab vedotin-piiq structure rendering